Man Group plc Has $18.83 Million Stock Position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Man Group plc lowered its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 21.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 146,970 shares of the specialty pharmaceutical company’s stock after selling 39,106 shares during the period. Man Group plc owned about 0.26% of Jazz Pharmaceuticals worth $18,832,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the company. Signaturefd LLC lifted its stake in shares of Jazz Pharmaceuticals by 56.3% in the second quarter. Signaturefd LLC now owns 200 shares of the specialty pharmaceutical company’s stock worth $29,000 after acquiring an additional 72 shares during the period. MUFG Americas Holdings Corp acquired a new stake in Jazz Pharmaceuticals during the 3rd quarter valued at approximately $29,000. Captrust Financial Advisors increased its position in Jazz Pharmaceuticals by 120.0% during the 2nd quarter. Captrust Financial Advisors now owns 220 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 120 shares during the period. Stonebridge Capital Advisors LLC bought a new position in Jazz Pharmaceuticals during the 2nd quarter worth approximately $37,000. Finally, AdvisorNet Financial Inc bought a new position in Jazz Pharmaceuticals during the 3rd quarter worth approximately $37,000. 89.10% of the stock is owned by hedge funds and other institutional investors.

In other news, CEO Bruce C. Cozadd sold 500 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $130.00, for a total transaction of $65,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 4.30% of the company’s stock.

A number of research firms have recently commented on JAZZ. Piper Jaffray Companies lowered shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $205.00 to $142.00 in a research note on Wednesday, August 21st. ValuEngine raised shares of Jazz Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 2nd. BidaskClub raised shares of Jazz Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, November 27th. Wells Fargo & Co restated a “buy” rating on shares of Jazz Pharmaceuticals in a report on Wednesday, August 14th. Finally, HC Wainwright reaffirmed a “hold” rating and set a $147.00 price target on shares of Jazz Pharmaceuticals in a research report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $167.00.

NASDAQ:JAZZ opened at $150.38 on Tuesday. The company has a fifty day moving average of $132.43 and a 200-day moving average of $132.84. The firm has a market capitalization of $8.55 billion, a P/E ratio of 10.92, a P/E/G ratio of 1.18 and a beta of 1.15. The company has a quick ratio of 3.71, a current ratio of 3.89 and a debt-to-equity ratio of 0.56. Jazz Pharmaceuticals PLC has a twelve month low of $113.52 and a twelve month high of $154.44.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Tuesday, November 5th. The specialty pharmaceutical company reported $4.10 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.19 by $0.91. The business had revenue of $537.70 million for the quarter, compared to analyst estimates of $523.92 million. Jazz Pharmaceuticals had a net margin of 29.61% and a return on equity of 27.99%. Jazz Pharmaceuticals’s revenue was up 14.6% on a year-over-year basis. During the same period in the prior year, the firm earned $3.58 earnings per share. On average, analysts anticipate that Jazz Pharmaceuticals PLC will post 14.15 EPS for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

See Also: Hedge Funds – Risk or Reward?

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.